المؤلفون: Thomas, Quentin Dominique, Boussere, Amal, Classe, Jean-Marc, Pomel, Christophe, Costaz, Hélène, Rodrigues, Manuel, Ray-Coquard, Isabelle, Gladieff, Laurence, Rouzier, Roman, Rouge, Thibault de la Motte, Gouy, Sébastien, Barranger, Emmanuel, Sabatier, Renaud, Floquet, Anne, Marchal, Frédéric, Guillemet, Cécile, Polivka, Valentine, Martin, Anne-Laure, Colombo, Pierre-Emmanuel, Fiteni, Frédéric

المساهمون: Institut régional de Cancérologie de Montpellier (ICM), CRLCC René Gauducheau, Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne (UCA), Centre Jean Perrin Clermont-Ferrand (UNICANCER/CJP), UNICANCER, Service de chirurgie Centre Georges-François Leclerc, Centre Régional de Lutte contre le cancer Georges-François Leclerc Dijon (UNICANCER/CRLCC-CGFL), UNICANCER-UNICANCER, Institut Curie Paris, Centre Léon Bérard Lyon, Institut Claudius Regaud, Centre Régional de Lutte contre le Cancer François Baclesse Caen (UNICANCER/CRLC), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN), CRLCC Eugène Marquis (CRLCC), Institut Gustave Roussy (IGR), Centre de Lutte contre le Cancer Antoine Lacassagne Nice (UNICANCER/CAL), UNICANCER-Université Côte d'Azur (UniCA), Institut Paoli-Calmettes (IPC), Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Institut Bergonié Bordeaux, Institut de Cancérologie de Lorraine - Alexis Vautrin Nancy (UNICANCER/ICL), Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Institut Desbrest de santé publique (IDESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)

المصدر: ISSN: 0090-8258.

مصطلحات موضوعية: Neoadjuvant, Cytoreduction, Survival, Prognosis, Propensity score, [SDV.CAN]Life Sciences [q-bio]/Cancer

الوصف: International audience ; Objective. Interval debulking surgery is recommended after 3–4 cycles (standard IDS) of neoadjuvant chemotherapy (NACT) for epithelial ovarian cancer (EOC) not able to received upfront complete debulking surgery. However, real world practices frequently report performing IDS after ≥5 NAC cycles (delayed IDS). The aim of this work was to evaluate the impact on survival of the number of NACT cycles before IDS.Methods. We identified from a French national database, women with newly diagnosed EOC who underwent IDS from January 2011 to December 2016. Progression free survival (PFS) and overall survival (OS) were compared using Cox model with adjustments for confounding factors provided by two propensity score methods: inverse probability of treatment weighting (IPTW) and matched-pair analysis.Results. 928 patients treated by IDS for which our propensity score could be applied were identified. After a median follow-up of 49.0 months (95% CI [46.0;52.9]); from the IPTW analysis, median PFS was 17.6 months and 11.5 months (HR = 1.42; CI 95% [1.22–1.67]; p < 0.0001); median OS was 51.2 months and 44.3 months (HR = 1.29; CI 95% [1.06–1.56]; p = 0.0095) for the standard and delayed IDS groups. From the matched-pair analysis (comparing 352 patients for each group), standard IDS was associated with better PFS (HR = 0,77; CI 95% [0.65–0.90]; p = 0.018) but not significantly associated with better OS (HR = 0,84; CI 95% [0.68–1,03]; p = 0.0947).Conclusions. Carrying IDS after ≥5 NACT cycles seems to have a negative effect on patients survival. The goal of IDS surgery is complete resection and should not be performed after >3–4 NACT cycles.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/35970603; hal-03868125; https://hal.science/hal-03868125Test; https://hal.science/hal-03868125/documentTest; https://hal.science/hal-03868125/file/1-s2.0-S0090825822005431-main.pdfTest; PUBMED: 35970603

الإتاحة: https://doi.org/10.1016/j.ygyno.2022.08.005Test
https://hal.science/hal-03868125Test
https://hal.science/hal-03868125/documentTest
https://hal.science/hal-03868125/file/1-s2.0-S0090825822005431-main.pdfTest

المؤلفون: De Nonneville, Alexandre, Zemmour, Christophe, Frank, Sophie, Joly, Florence, Ray-Coquard, Isabelle, Costaz, Helene, Classe, Jean-Marc, Floquet, Anne, De La Motte Rouge, Thibault, Colombo, Pierre-Emmanuel, Sauterey, Baptiste, Leblanc, Eric, Pomel, Christophe, Marchal, Frederic, Barranger, Emmanuel, Savoye, Aude-Marie, Guillemet, Cecile, Petit, Thierry, Pautier, Patricia, Rouzier, Roman, Gladieff, Laurence, Simon, Gaetane, Courtinard, Coralie, Sabatier, Renaud

المساهمون: INSERM, Université de Lille, Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192

مصطلحات موضوعية: Endometrioid, Ovarian cancer, Survival, Epidemiology, Prognostic factors

الوصف: BACKGROUND: Prognostic significance of endometrioid epithelial ovarian cancer (EOC) is controversial. We compared clinical, pathological, and biological features of patients with endometrioid and serous EOC, and assessed the independent effect of histology on outcomes. METHODS: We conducted a multicenter retrospective analysis of patients with EOC selected from the French Epidemiological Strategy and Medical Economics OC database between 2011 and 2016. Our main objective was to compare overall survival (OS) in endometrioid and serous tumors of all grades. Our second objectives were progression-free survival (PFS) and prognostic features. RESULTS: Out of 10,263 patients included, 3180 cases with a confirmed diagnosis of serous (N = 2854) or endometrioid (N = 326) EOC were selected. Patients with endometrioid histology were younger, more often diagnosed at an early stage, with lower-grade tumors, more frequently dMMR/MSI-high, and presented more personal/familial histories of Lynch syndrome-associated cancers. BRCA1/2 mutations were more frequently identified in the serous population. Endometrioid patients were less likely to receive chemotherapy, with less bevacizumab. After median follow-up of 51.7 months (95CI[50.1-53.6]), five-year OS rate was 81% (95CI[74-85]) in the endometrioid subgroup vs. 55% (95CI[53-57] in the serous subset (p < 0.001, log-rank test). In multivariate analyses including [age, ECOG-PS, FIGO, grade, and histology], the endometrioid subtype was independently associated with better OS (HR = 0.38, 95CI[0.20-0.70], p= 0.002) and PFS (HR = 0.53, 95CI[0.37-0.75], p < 0.001). CONCLUSIONS: Clinicopathological features at diagnosis are not the same for endometrioid and serous EOC. Endometrioid histology is an independent prognosis factor in EOC. These observations suggest the endometrioid population requires dedicated clinical trials and management.

العلاقة: Gynecologic oncology; Gynecol Oncol; http://hdl.handle.net/20.500.12210/75252Test

الإتاحة: https://doi.org/20.500.12210/75252Test
https://hdl.handle.net/20.500.12210/75252Test

المؤلفون: Clatot, Florian, Philippin-Lauridant, Géraldine, Ouvrier, Matthieu-John, Nakry, Tony, Laberge-Le-Couteulx, Sophie, Guillemet, Cécile, Veyret, Corinne, Blot, Emmanuel

المصدر: Journal of Neuro-Oncology; Dec2009, Vol. 95 Issue 3, p421-426, 6p, 1 Diagram, 4 Charts, 1 Graph

مستخلص: Leptomeningeal meningitis occurs in approximately 5% of metastatic breast cancers, and there is no standard treatment for this complication. We retrospectively analyzed the clinical data and cerebrospinal fluid of 24 patients treated with high-dose intrathecal methotrexate for breast cancer leptomeningeal meningitis (BLM). Cytologic response (CSF cytology without neoplastic cells after treatment) was observed in 11 patients (46%) and related to survival ( P = 0.005). In addition, clinical symptoms improved in all 11 patients who had a cytologic response and in 7 patients (54%) without cytologic response ( P = 0.02). The predictive value of cytologic response needs further confirmation. Cytologic response could be helpful in the management of intrathecal chemotherapy in patients with BLM. [ABSTRACT FROM AUTHOR]

: Copyright of Journal of Neuro-Oncology is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Blot, Emmanuel, Couteulx, Sophie Laberge-Le, Jamali, Hossein, Cornic, Marie, Guillemet, Cécile, Duval, Christian, Hellot, Marie-France, Pille, Jean-Yves, Picquenot, Jean-Michel, Veyret, Corinne

المصدر: Breast Journal; May/Jun2008, Vol. 14 Issue 3, p268-274, 7p, 1 Color Photograph, 5 Charts, 2 Graphs

مصطلحات موضوعية: BREAST cancer, CANCER patients, CANCER invasiveness, METASTASIS, CELL membranes, IMMUNOHISTOCHEMISTRY

مستخلص: CXC chemokine receptor 4 (CXCR4) has been reported to be involved in organ-specific homing of breast cancer-derived metastasis. We investigated CXCR4 expression by immunohistochemistry as a possible new prognostic factor for primary breast cancer. Two groups of women treated for breast cancer in 1991 at the Centre for the fight against cancer of Upper Normandy—France (Centre de Lutte contre le Cancer de Haute Normandie) were assessed retrospectively. CXCR4 expression was evaluated using standard immunohistochemistry. Usual prognostic factors were recorded in the computer database. Final date of follow-up was December 31, 2001. Tissues were available for 110 node-positive and 84 node-negative breast cancer patients treated in 1991. CXCR4 membrane staining was considered a strong prognostic factor for both 10-year metastasis-free- (p < 0.0001) and overall survival (p < 0.0001) in node-negative but not in node-positive breast cancer patients. CXCR4 cytoplasmic staining was not considered a significant prognostic factor. Our results suggest that CXCR4 membrane staining could be considered a new prognostic factor. Moreover, targeting CXCR4 in primary breast cancer patients may be a new therapeutic concept. However, these results warrant further investigation. [ABSTRACT FROM AUTHOR]

: Copyright of Breast Journal is the property of Hindawi Limited and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Isambert, Nicolas¹ nisambert@cgfl.fr, Ray-Coquard, Isabelle², Italiano, Antoine³, Rios, Maria⁴, Kerbrat, Pierre⁵, Gauthier, Mélanie¹, Blouet, Aurélien⁶, Chaigneau, Loïc⁷, Duffaud, Florence⁸, Piperno-Neumann, Sophie⁹, Kurtz, Jean-Emmanuel¹⁰, Girard, Nicolas¹¹, Collard, Olivier¹², Bompas, Emmanuelle¹³, Penel, Nicolas¹⁴, Bay, Jacques-Olivier¹⁵, Guillemet, Cécile¹⁶, Collin, Françoise¹, Blay, Jean-Yves², Le Cesne, Axel¹⁷

المصدر: European Journal of Cancer. Jan2014, Vol. 50 Issue 1, p128-136. 9p.

مصطلحات موضوعية: *CANCER chemotherapy, *HEART tumors, *PROBABILITY theory, *SURVIVAL, *RETROSPECTIVE studies, *DESCRIPTIVE statistics

مصطلحات جغرافية: FRANCE

مستخلص: Abstract: Introduction: Primary cardiac sarcomas (PCS) are rare tumours of dismal prognosis. Methods: Data of 124 patients with PCS referred to institutions of the French Sarcoma Group (FSG) from 1977 and 2010 were reviewed. Results: Median age was 48.8years. PCS were poorly-differentiated sarcomas (N =45, 36.3%), angiosarcomas (N =40, 32.3%), leiomyosarcomas (N =16, 12.9%) and others (N =23, 18.6%). At diagnosis, 100 patients (80.6%) were localised and 24 (19.4%) metastatic. Tumours were located in the right (N =47, 38.8%), left atrial cavities (N =45, 37.2%) or encompassed several locations in nine cases (7.4%). Surgery was performed in 81 cases (65.3%). Heart transplant was performed in five patients. Radiotherapy adjuvant (N =18, 14.5%) or alone (N =6, 4.8%) was performed in non-metastatic patients only (N =24, 19.4%). With a median follow-up of 51.2months, median overall survival (OS) was 17.2months for the entire cohort, 38.8months after complete resection versus 18.2 after incomplete resection and 11.2months in non-resected patients. Radiotherapy was associated with improved progression-free survival (PFS) on multivariate analysis. Chemotherapy was significantly associated with better OS only in non-operated patients but not in operated patients. In non-metastatic patients, surgery (hazard ratio [HR]=0.42, p <0.001), male gender (HR=0.56, p =.032) was associated with better OS and surgery (HR=0.61; p =.076), radiotherapy (HR=0.43; p =.004) and chemotherapy (HR=0.30, p =.003) improved PFS. Conclusion: Only surgical resection is associated with a perspective of prolonged survival. Chemotherapy is associated with a better outcome in non-resected patients. [Copyright &y& Elsevier]